Effect of Recombinant Human Growth Hormone and Rosiglitazone for HIV-Associated Abdominal Fat Accumulation on Adiponectin and other Markers of Inflammation

References

• Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48–62.10.1056/NEJMra041811
   PubMed Web of Science ®Google Scholar
• Frystyk J, Berne C, Berglund L, Jensevik K, Flyvbjerg A, Zethelius B. Serum adiponectin is a predictor of coronary heart disease: A population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab. 2007;92:571–576.10.1210/jc.2006-1067
   PubMed Web of Science ®Google Scholar
• Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. J Am Med Assoc. 2004;291:1730–1737.10.1001/jama.291.14.1730
   PubMed Web of Science ®Google Scholar
• Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: An individual participant meta-analysis. J Am Med Assoc. 2005;294:1799–1809.
   PubMed Web of Science ®Google Scholar
• Bostom AG, Silbershatz H, Rosenberg IH, Selhub J, D’Agostino RB, Wolf PA, et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly framingham men and women. Arch Intern Med. 1999;159:1077–1080.10.1001/archinte.159.10.1077
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767–1772.10.1161/01.CIR.101.15.1767
   PubMed Web of Science ®Google Scholar
• Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165–1168.10.1016/0140-6736(93)90998-V
   PubMed Web of Science ®Google Scholar
• Held C, Hjemdahl P, Rehnqvist N, Wallen NH, Bjorkander I, Eriksson SV, et al. Fibrinolytic variables and cardiovascular prognosisin patients with stable angina pectoris treated with verapamil or metoprolol: Results from the angina prognosis study in stockholm. Circulation. 1997;95:2380–2386.10.1161/01.CIR.95.10.2380
   PubMed Web of Science ®Google Scholar
• van der Bom JG, de KP, Haverkate F, Bots ML, Meijer P, de Jong PT, et al. Tissue plasminogen activator and risk of myocardial infarction: The rotterdam study. Circulation. 1997;95:2623–2627.10.1161/01.CIR.95.12.2623
   PubMed Web of Science ®Google Scholar
• Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, et al. Inflammatory markers and onset of cardiovascular events: Results from the health ABC study. Circulation. 2003;108:2317–2322.10.1161/01.CIR.0000097109.90783.FC
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101:2149–2153.10.1161/01.CIR.101.18.2149
   PubMed Web of Science ®Google Scholar
• Galea J, Armstrong J, Gadsdon P, Holden H, Francis SE, Holt CM. Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol. 1996;16:1000–1006.10.1161/01.ATV.16.8.1000
   PubMed Web of Science ®Google Scholar
• Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest. 1997;99:2752–2761.10.1172/JCI119465
   PubMed Web of Science ®Google Scholar
• De Luca A, de Gaetano DK, Colafigli M, Cozzi-Lepri A, DeCurtis A, Gori A, et al. The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: A nested case-control study. BMC Infect Dis. 2013;13:414.
   PubMed Web of Science ®Google Scholar
• Hileman CO, Longenecker CT, Carman TL, McComsey GA. C-reactive protein predicts 96-week carotid intima media thickness progression in HIV-infected adults naive to antiretroviral therapy. J Acquir Immune Defic Syndr. 2014;65:340–344.10.1097/QAI.0000000000000063
   PubMed Web of Science ®Google Scholar
• Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr. 2009;51:268–273.10.1097/QAI.0b013e3181a9992c
   PubMed Web of Science ®Google Scholar
• Knudsen A, Katzenstein TL, Benfield T, Jorgensen NR, Kronborg G, Gerstoft J, et al. Plasma plasminogen activator inhibitor-1 predicts myocardial infarction in HIV-1-infected individuals. Acquir Immune Defic Syndr. 2014;28:1171–1179.10.1097/QAD.0000000000000247
   Web of Science ®Google Scholar
• Shikuma CM, Barbour JD, Ndhlovu LC, Keating SM, Norris PJ, Budoff M, et al. Plasma monocyte chemoattractant protein-1 and tumor necrosis factor-α levels predict the presence of coronary artery calcium in HIV-infected individuals independent of traditional cardiovascular risk factors. AIDS Res Hum Retroviruses. 2014;30:142–146.10.1089/aid.2013.0183
   PubMed Web of Science ®Google Scholar
• He G, Andersen O, Haugaard SB, Lihn AS, Pedersen SB, Madsbad S, Richelsen B. Plasminogen activator inhibitor type 1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines. Eur J Clin Invest. 2005;35:583–590.10.1111/eci.2005.35.issue-9
   PubMed Web of Science ®Google Scholar
• Lihn AS, Richelsen B, Pedersen SB, Haugaard SB, Rathje GS, Madsbad S, Andersen O. Increased expression of TNF-α, IL-6, and IL-8 in HALS: Implications for reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol Metab. 2003;285:E1072–E1080.10.1152/ajpendo.00206.2003
   PubMed Web of Science ®Google Scholar
• Johnson JA, Albu JB, Engelson ES, Fried SK, Inada Y, Ionescu G, Kotler DP. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrinol Metab. 2004;286:E261–E271.
   PubMed Web of Science ®Google Scholar
• Gavrila A, Chan JL, Yiannakouris N, Kontogianni M, Miller LC, Orlova C, Mantzoros CS. Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: Cross-sectional and interventional studies. J Clin Endocrinol Metab. 2003;88:4823–4831.10.1210/jc.2003-030214
   PubMed Web of Science ®Google Scholar
• Grunfeld C, Thompson M, Brown SJ, Richmond G, Lee D, Muurahainen N, Kotler DP. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr. 2007;45:286–297.
   PubMed Web of Science ®Google Scholar
• Kotler DP, Muurahainen N, Grunfeld C, Wanke C, Thompson M, Saag M, et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr. 2004;35:239–252.10.1097/00126334-200403010-00004
   PubMed Web of Science ®Google Scholar
• Kotler DP, Muurahainen N, Grunfeld C, Wanke C, Thompson M, Saag M, et al. Effects of growth hormone on visceral adipose tissue and dyslipidemia in HIV, an erratum. J Acquir Immune Defic Syndr. 2006;43:378–380.10.1097/01.qai.0000243108.26136.66
   PubMed Web of Science ®Google Scholar
• Glesby MJ, Albu J, Chiu YL, Ham K, Engelson E, He Q, et al. Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: A randomized, double-blind, placebo-controlled, factorial trial. PLoS ONE. 2013;8:e61160.10.1371/journal.pone.0061160
   PubMed Web of Science ®Google Scholar
• Engelson ES, Kotler DP, Tan Y, Agin D, Wang J, Pierson RN Jr, Heymsfield SB. Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Am J Clin Nutr. 1999;69:162–169.
   Web of Science ®Google Scholar
• Molarius A, Seidell JC. Selection of anthropometric indicators for classification of abdominal fatness–a critical review. Int J Obes Relat Metab Disord. 1998;22:719–727.10.1038/sj.ijo.0800660
   PubMed Web of Science ®Google Scholar
• Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402–2410.10.1210/jcem.85.7.6661
   PubMed Web of Science ®Google Scholar
• Bezante GP, Briatore L, Rollando D, Maggi D, Setti M, Ghio M, et al. Hypoadiponectinemia in lipodystrophic HIV individuals: A metabolic marker of subclinical cardiac damage. Nutr Metab Cardiovasc Dis. 2009;19:277–282.10.1016/j.numecd.2008.07.009
   PubMed Web of Science ®Google Scholar
• Ketlogetswe KS, Post WS, Li X, Palella FJ Jr, Jacobson LP, Margolick JB, et al. Lower adiponectin is associated with subclinical cardiovascular disease among HIV-infected men. AIDS. 2014;28:901–909.10.1097/QAD.0000000000000186
   PubMed Web of Science ®Google Scholar
• Lo J, You SM, Canavan B, Liebau J, Beltrani G, Koutkia P, et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation. J Am Med Assoc. 2008;300:509–519.10.1001/jama.300.5.509
   PubMed Web of Science ®Google Scholar
• Tsuchida A, Yamauchi T, Takekawa S, Hada Y, Ito Y, Maki T, Kadowaki T. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: Comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes. 2005;54:3358–3370.10.2337/diabetes.54.12.3358
   PubMed Web of Science ®Google Scholar
• Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care. 2002;25:376–380.10.2337/diacare.25.2.376
   PubMed Web of Science ®Google Scholar
• Hung YJ, Lin SH, Pei D, Kuo SW, Hsieh CH, He CT, et al. Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: The role of adiponectin and C-reactive protein. Metabolism. 2006;55:439–444.10.1016/j.metabol.2005.10.004
   PubMed Web of Science ®Google Scholar
• Kim SG, Ryu OH, Kim HY, Lee KW, Seo JA, Kim NH, et al. Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome. Eur J Endocrinol. 2006;154:433–440.10.1530/eje.1.02100
   PubMed Web of Science ®Google Scholar
• Majuri A, Santaniemi M, Rautio K, Kunnari A, Vartiainen J, Ruokonen A, et al. Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. Eur J Endocrinol. 2007;156:263–269.10.1530/eje.1.02331
   PubMed Web of Science ®Google Scholar
• Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy. Ann Intern Med. 2004;140:786–794.10.7326/0003-4819-140-10-200405180-00008
   PubMed Web of Science ®Google Scholar
• Tien PC, Choi AI, Zolopa AR, Benson C, Tracy R, Scherzer R, et al. Inflammation and mortality in HIV-infected adults: Analysis of the FRAM study cohort. J Acquir Immune Defic Syndr. 2010;55:316–322.10.1097/QAI.0b013e3181e66216
   PubMed Web of Science ®Google Scholar
• Feldman JG, Goldwasser P, Holman S, DeHovitz J, Minkoff H. C-Reactive protein is an independent predictor of mortality in women with HIV-1 infection. J Acquir Immune Defic Syndr. 2003;32:210–214.10.1097/00126334-200302010-00014
   PubMed Web of Science ®Google Scholar
• Westhorpe CL, Schneider HG, Dunne M, Middleton T, Sundararajan V, Spelman T, et al. C-reactive protein as a predictor of cardiovascular risk in HIV-infected individuals. Sex Health. 2014;11:580–582.10.1071/SH14130
   PubMed Web of Science ®Google Scholar
• Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: Relationship with visceral adipose reduction. AIDS. 2011;25:1281–1288.10.1097/QAD.0b013e328347f3f1
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471.10.1056/NEJMoa072761
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Hafley G, Dickerson S, Burns S, Tourt-Uhlig S, White J, et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J. 2013;166:240–249.10.1016/j.ahj.2013.05.004
   PubMed Web of Science ®Google Scholar